Goldacre
EMA launches consultation on clinical trials
January 22, 2015Research and Development, Sales and Marketing EFPIA, EMA, EU, Europe, Goldacre, alltrials, transparency
The European Medicines Agency has invited pharma to comment on its proposals to ramp up transparency in the industry and …
Sharing trial data should be ‘expected norm’ says US think-tank
January 15, 2015Medical Communications, Research and Development, Sales and Marketing FDA, Goldacre, Institute of Medicine, clinical trials, transparency
Clinical trial data is in the public interest and should be shared no less than 30 days following regulatory approval …
EMA responds to redaction concerns
November 14, 2014Sales and Marketing AbbVie, EMA, Goldacre, Humira, Rasi, adalimumab, redactions, transparency
The EMA has published a response to European Ombudsman Emily O’Reilly’s questions about some of its trial data redactions. O’Reilly’s …
Janssen: why transparency is essential to the health of our industry
August 29, 2014Medical Communications, Research and Development, Sales and Marketing EFPIA, EMEA, Goldacre, Janssen, alltrials, transparency
The pharmaceutical industry is moving forward, working together to ensure patients have access to new and innovative medicines.However, more must …
Publish all clinical trials, say pharma doctors
August 29, 2014Research and Development, Sales and Marketing Goldacre, all trials, data, fpm, transparency
All clinical trials should be registered and published according to a recent survey conducted by the Faculty of Pharmaceutical Medicine. …
EMA delays trial transparency – again
July 10, 2014Medical Communications, Research and Development, Sales and Marketing EMA, Goldacre, Rasi, alltrials, clinical trials, transparency
The European Medicines Agency has once again said that it is to delay the launch of its new clinical trial …
EMA changes ‘on screen’ data policy
June 16, 2014Medical Communications, Research and Development, Sales and Marketing AbbVie, EMA, Goldacre, Humira, alltrials, transparency
The European Medicines Agency is to formally agree its policy on the vexed issue of the publication of clinical trial …
InterMune drops EMA lawsuit over data release
June 10, 2014Research and Development, Sales and Marketing EMA, EU, Esbriet, Goldacre, InterMune, alltrials, lung
InterMune has ended a year-long legal spat with the European Medicines Agency over the potential release of data for its …
Lilly the latest to open up data
June 4, 2014Medical Communications, Research and Development, Sales and Marketing Goldacre, NHS, alltrials, data, lilly, transparency, trials
Eli Lilly is to begin sharing its clinical trial data with scientific researchers through a website housing information from several …
NICE chair: pharma must show how it prices drugs
April 28, 2014Research and Development, Sales and Marketing Goldacre, Haslam, NICE, VBP, all trials, pars
The pharmaceutical industry must be willing to show the public how it prices its drugs – or face losing its …
EU votes for trial transparency
April 3, 2014Research and Development, Sales and Marketing ABPI, EFPIA, EU, Goldacre, UK, alltrials, transparency, willmott
Europe took a decisive step toward forcing pharma to open up its clinical trial data last night, after the EU …
Data transparency debate: Europe decides its future
March 24, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EFPIA, EMA, EU, Goldacre, NHS, alltrials, european, transparency
Transparency became a major issue in 2013 as various new pressure groups sprung up with the shared aim of forcing …
Novartis extends trial transparency
February 27, 2014Medical Communications, Research and Development, Sales and Marketing EFPIA, EMA, Goldacre, Novartis, alltrials, transparency
Novartis has become the latest pharmaceutical company to allow greater scrutiny of its clinical trial data.
J&J reveals more on transparency policy
February 3, 2014Medical Communications, Research and Development, Sales and Marketing Goldacre, J&J, JJ, alltrials, johnson, transparency, yoda
Johnson & Johnson’s pharma subsidiary Janssen has given Pharmafile more details on its new transparency policy, which will see both …
GSK and Sanofi expand transparency
January 6, 2014Research and Development, Sales and Marketing GSK, Goldacre, Sanofi, alltrials, transparency
GlaxoSmithKline and Sanofi have announced separate moves which will shine greater light on both companies’ clinical trial data. GSK has …
